trending Market Intelligence /marketintelligence/en/news-insights/trending/eF1vcbKHV2gyL_VRBrj5uw2 content esgSubNav
In This List

UK's NICE recommends Merck KGaA's head/neck cancer drug

Blog

Insight Weekly: Recession risk persists; Banks pull back from crypto; 2022 laggard stocks rally

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Blog

Insight Weekly: Inflation eases; bank M&A slows; top companies boost market share

Blog

Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet


UK's NICE recommends Merck KGaA's head/neck cancer drug

The U.K.'s National Institute for Health and Care Excellence recommended Merck KGaA's cancer drug Erbitux for routine use under the National Health Service.

Erbitux is used in combination with platinum-based chemotherapy for treating patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. The treatment has been available in England through the U.K.'s cancer drugs fund since 2010.

The decision confirms the positive benefit the drug can have on the survival of patients, Germany-based Merck said in a news release. The recommendation also secures access to Erbitux for new patients in England with oral cavity tumors.